NO20090583L - Terapi for alfa-galaktosidase A-mangel - Google Patents

Terapi for alfa-galaktosidase A-mangel

Info

Publication number: NO20090583L
Authority: NO; Norway
Prior art keywords: galactosidase; therapy; deficiency; alpha; sample
Prior art date: 1996-09-13

Application number

NO20090583A

Other languages

English (en)

Other versions

NO330687B1 (no

Inventor

Richard F Selden

Marianne Borowski

Francis P Gillespie

Carol M Kinoshita

Douglas A Treco

Melanie D Williams

Original Assignee

Shire Human Genetic Therapies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-13

Filing date

2009-02-06

Publication date

1999-05-10

1999-05-10 Publication of NO20090583L publication Critical patent/NO20090583L/no

2009-02-06 Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies

2011-06-06 Publication of NO330687B1 publication Critical patent/NO330687B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Obesity (AREA)
Hematology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)

NO20090583A 1996-09-13 2009-02-06 Fremgangsmate for rensing av human alfa-galaktosidase A NO330687B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US71261496A	1996-09-13	1996-09-13
PCT/US1997/016603 WO1998011206A2 (en)	1996-09-13	1997-09-12	THERAPY FOR α-GALACTOSIDASE A DEFICIENCY

Publications (2)

Publication Number	Publication Date
NO20090583L true NO20090583L (no)	1999-05-10
NO330687B1 NO330687B1 (no)	2011-06-06

Family

ID=24862863

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO19991225A NO328443B1 (no)	1996-09-13	1999-03-12	DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert.
NO20090583A NO330687B1 (no)	1996-09-13	2009-02-06	Fremgangsmate for rensing av human alfa-galaktosidase A
NO20110496A NO340408B1 (no)	1996-09-13	2011-03-31	Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no)	1996-09-13	2014-09-29	Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO19991225A NO328443B1 (no)	1996-09-13	1999-03-12	DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert.

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20110496A NO340408B1 (no)	1996-09-13	2011-03-31	Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no)	1996-09-13	2014-09-29	Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Country Status (20)

Country	Link
EP (4)	EP1538202B1 (no)
JP (7)	JP4001925B2 (no)
KR (2)	KR100547402B1 (no)
CN (1)	CN1268741C (no)
AT (1)	ATE286120T1 (no)
AU (1)	AU4424497A (no)
CA (1)	CA2265464C (no)
DE (1)	DE69732129T2 (no)
DK (2)	DK1538202T3 (no)
ES (3)	ES2458292T3 (no)
HU (2)	HU227189B1 (no)
IL (2)	IL128960A (no)
MX (1)	MX340738B (no)
NO (4)	NO328443B1 (no)
NZ (2)	NZ334721A (no)
PL (1)	PL190041B1 (no)
PT (1)	PT1538202E (no)
RU (1)	RU2179034C2 (no)
TW (1)	TW585919B (no)
WO (1)	WO1998011206A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en)	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
EP2147681A1 (en) *	1997-10-29	2010-01-27	Genzyme Corporation	Compositions and methods for treating lysosomal storage disease
EP1658857A1 (en) *	1997-10-29	2006-05-24	Genzyme Corporation	Compositions and methods for treating lysosomal storage disease
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
AU2012241170B2 (en) *	1999-03-11	2016-07-28	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
AU2016250357B2 (en) *	1999-03-11	2018-11-01	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
AU2004242550B2 (en) *	1999-03-11	2008-04-03	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
EP2275559A3 (en) *	1999-09-28	2011-03-23	Shire Human Genetic Therapies, Inc.	Optimized messenger RNA
WO2002064799A2 (en)	1999-09-28	2002-08-22	Transkaryotic Therapies, Inc.	Optimized messenger rna
AU1647501A (en)	1999-12-10	2001-06-18	Cytos Biotechnology Ag	Replicon based activation of endogenous genes
BR0108077A (pt)	2000-02-04	2002-10-22	Children S Hospital Res Founda	Processo para reduzir placas ateroscleróticas em um mamìfero, método para tratamento da aterosclerose em um mamìfero, composição, métodos para prover proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo ou mistura deles, para células de um mamìfero tendo deficiência na proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo , para prover lipase de ácido lisossomal biologicamente ativa para células de um mamìfero tendo deficiência de lipase de ácido lisossomal biologicamente ativa, para prover lipase de ácido lisossoal biologicamente ativa para células de um mamìfero com aterosclerose, para tratamento da doença de wolman em um mamìfero, para tratamento de doença de armazenagem de colesteril éster em um mamìfero, e, para tratamento da aterosclerose em um mamìfero
US20020095135A1 (en)	2000-06-19	2002-07-18	David Meeker	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) *	2000-08-18	2006-11-21	Shire Human Genetic Therapies, Inc.	High mannose proteins and methods of making high mannose proteins
IL140110A0 (en) *	2000-12-05	2002-02-10	Applied Research Systems	Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
NZ536361A (en)	2002-04-25	2008-05-30	Shire Human Genetic Therapies	Treatment of alpha-galactosidase a deficiency
JP5433133B2 (ja) *	2003-01-22	2014-03-05	デューク・ユニヴァーシティ	リソソームポリペプチドを発現するための改善された構築物
CA2626092A1 (en)	2005-11-18	2007-05-24	Tokyo Metropolitan Organization For Medical Research	Novel highly functional enzyme having modified substrate-specificity
AR059089A1 (es) *	2006-01-20	2008-03-12	Genzyme Corp	Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2391657T3 (es)	2006-02-07	2012-11-28	Shire Human Genetic Therapies, Inc.	Composiciones estabilizadas de proteínas que tienen un resto tiol libre
CN101404927A (zh)	2006-02-09	2009-04-08	建新公司	慢速脑室内递送
ES2549121T3 (es)	2007-05-18	2015-10-23	Tokyo Metropolitan Institute Of Medical Science	Composición farmacéutica para terapia de reemplazo enzimático
MX2011006347A (es)	2008-12-16	2011-09-06	Genzyme Corp	Conjugados de oligosacaridos-proteinas.
MX379016B (es)	2009-07-28	2025-03-10	Takeda Pharmaceuticals Co	Composiciones y metodos para tratar enfermedad de gaucher.
HUE033217T2 (hu)	2010-04-23	2017-11-28	Alexion Pharma Inc	Lizoszomális tárolási betegséggel asszociált enzim
US9453847B2 (en)	2010-07-19	2016-09-27	Shire Human Genetic Therapies, Inc.	Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof
ME02062B (me)	2010-09-09	2015-05-20	Synageva Biopharma Corp	Primena lizozomalne kisele lipaze za lecenje nedostatka lizozomalne kisele lipaze kod pacijenata
EP2675472A4 (en)	2011-02-15	2014-09-17	Synageva Biopharma Corp	METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
US20140301977A1 (en) *	2011-11-02	2014-10-09	Genentech, Inc.	Overload and elute chromatography
CA2865614A1 (en)	2012-03-02	2013-09-06	Shire Human Genetic Therapies, Inc.	Compositions and methods for treating type iii gaucher disease
JP6368304B2 (ja) *	2012-06-29	2018-08-01	コンセホスペリオールデインベスティガシオネスシエンティフィカス（セエセイセ）ＣｏｎｓｅｊｏＳｕｐｅｒｉｏｒＤｅＩｎｖｅｓｔｉｇａｃｉｏｎｅｓＣｉｅｎｔｉｆｉｃａｓ（Ｃｓｉｃ）	生物活性化合物の送達に有用な機能性リポソーム
WO2014016873A1 (en) *	2012-07-26	2014-01-30	Jcr Pharmaceuticals Co., Ltd.	Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) *	2012-07-26	2017-11-08	Ｊｃｒファーマ株式会社	組換えヒトα−ガラクトシダーゼＡの製造方法
CN105777862A (zh)	2012-10-24	2016-07-20	建新公司	使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
TWI642782B (zh) *	2013-10-23	2018-12-01	健臻公司	重組醣蛋白及其用途
JP6650943B2 (ja)	2014-12-22	2020-02-19	コデクシス，インコーポレイテッド	ヒトα−ガラクトシダーゼバリアント
WO2016116966A1 (en)	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) *	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
CN116270739A (zh)	2017-06-30	2023-06-23	富士胶片株式会社	细胞结构体在制造溶酶体贮积病处置剂中的用途
ES2716305B2 (es)	2017-12-11	2019-11-27	Fund Biomedica Galicia Sur	Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
MY207075A (en)	2018-12-20	2025-01-28	Codexis Inc	Human alpha-galactosidase variants
CN111308095A (zh) *	2020-03-04	2020-06-19	北京师范大学	用于诊断前列腺癌的尿液蛋白标记物
TW202423959A (zh) *	2022-08-24	2024-06-16	美商步行魚醫療公司	用於治療法布瑞氏症(fabry disease)之組成物及方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2619719B1 (fr) *	1987-09-01	1991-05-10	Sanofi Sa	Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
FI96121C (fi) *	1987-10-02	1996-05-10	Zymogenetics Inc	DNA-rakenne ja menetelmä heterologisen proteiinin tuottamiseksi
US5179023A (en)	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) *	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
NZ234453A (en) *	1989-07-13	1993-01-27	Sanofi Sa	Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
IL95330A0 (en) *	1989-08-11	1991-06-30	Lilly Co Eli	Expression of a functional insect specific toxin gene in mammalian cells
CA2092823A1 (en) *	1990-09-28	1992-03-29	Barry D. Greenberg	Transgenic animals with alzheimer's amyloid precursor gene
US5356804A (en)	1990-10-24	1994-10-18	Mount Sinai School Of Medicine Of The City Of New York	Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) *	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
JPH06503479A (ja) *	1991-10-16	1994-04-21	オラージェン，　インコーポレイテッド	動物体細胞の粒子−媒介トランスフォーメーション
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
NZ245015A (en) *	1991-11-05	1995-12-21	Transkaryotic Therapies Inc	Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
SE9300105D0 (sv) *	1993-01-15	1993-01-15	Kabi Pharmacia Ab	Stable protein solution
JPH09500269A (ja) *	1993-07-02	1997-01-14	インサイトファーマシューティカルズ，インク．	殺菌性／透過性が増大したグリコシル化及び非グリコシル化タンパク質及びその製造方法
NZ278809A (en)	1994-01-13	1998-03-25	Rogosin Inst	Macroencapsulation of secretory cells in an agarose collagen gel material coated with agarose
JP2984552B2 (ja) *	1994-09-02	1999-11-29	大和化成株式会社	ラッカーゼおよびその生産方法
US5541087A (en) *	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
JPH08196293A (ja) *	1995-01-25	1996-08-06	Mitsui Toatsu Chem Inc	タンパク質の製造方法
MX9705943A (es) *	1995-02-15	1997-10-31	Amgen Inc	Analogos de ligando mpl.

1997
- 1997-09-12 PL PL97332188A patent/PL190041B1/pl unknown
- 1997-09-12 HU HU9904666A patent/HU227189B1/hu unknown
- 1997-09-12 ES ES04030107.9T patent/ES2458292T3/es not_active Expired - Lifetime
- 1997-09-12 NZ NZ334721A patent/NZ334721A/xx not_active IP Right Cessation
- 1997-09-12 HU HU1000445A patent/HU230275B1/hu unknown
- 1997-09-12 WO PCT/US1997/016603 patent/WO1998011206A2/en not_active Ceased
- 1997-09-12 EP EP04030107.9A patent/EP1538202B1/en not_active Expired - Lifetime
- 1997-09-12 DE DE69732129T patent/DE69732129T2/de not_active Expired - Lifetime
- 1997-09-12 KR KR1019997002088A patent/KR100547402B1/ko not_active Expired - Lifetime
- 1997-09-12 MX MX2014010892A patent/MX340738B/es unknown
- 1997-09-12 AU AU44244/97A patent/AU4424497A/en not_active Abandoned
- 1997-09-12 CA CA002265464A patent/CA2265464C/en not_active Expired - Lifetime
- 1997-09-12 PT PT40301079T patent/PT1538202E/pt unknown
- 1997-09-12 NZ NZ506214A patent/NZ506214A/xx not_active IP Right Cessation
- 1997-09-12 DK DK04030107.9T patent/DK1538202T3/en active
- 1997-09-12 DK DK10181859.9T patent/DK2374876T3/en active
- 1997-09-12 ES ES10181859.9T patent/ES2581828T3/es not_active Expired - Lifetime
- 1997-09-12 RU RU99107287/14A patent/RU2179034C2/ru active
- 1997-09-12 AT AT97942567T patent/ATE286120T1/de active
- 1997-09-12 ES ES97942567T patent/ES2234032T3/es not_active Expired - Lifetime
- 1997-09-12 IL IL128960A patent/IL128960A/en not_active IP Right Cessation
- 1997-09-12 KR KR1020057011793A patent/KR20050084473A/ko not_active Ceased
- 1997-09-12 CN CNB97197909XA patent/CN1268741C/zh not_active Expired - Lifetime
- 1997-09-12 EP EP97942567A patent/EP0935651B1/en not_active Expired - Lifetime
- 1997-09-12 EP EP10181859.9A patent/EP2374876B1/en not_active Expired - Lifetime
- 1997-09-12 EP EP10181991A patent/EP2327775A3/en not_active Withdrawn
- 1997-09-12 JP JP51400498A patent/JP4001925B2/ja not_active Expired - Lifetime
- 1997-09-13 TW TW086113342A patent/TW585919B/zh not_active IP Right Cessation
1999
- 1999-03-12 NO NO19991225A patent/NO328443B1/no not_active IP Right Cessation
2006
- 2006-07-18 JP JP2006195854A patent/JP4313381B2/ja not_active Expired - Lifetime
2007
- 2007-06-13 JP JP2007155943A patent/JP4313405B2/ja not_active Expired - Lifetime
- 2007-07-16 IL IL184637A patent/IL184637A/en not_active IP Right Cessation
2008
- 2008-11-26 JP JP2008300335A patent/JP5590788B2/ja not_active Expired - Lifetime
- 2008-11-26 JP JP2008300426A patent/JP2009060918A/ja not_active Withdrawn
2009
- 2009-02-06 NO NO20090583A patent/NO330687B1/no not_active IP Right Cessation
2011
- 2011-03-31 NO NO20110496A patent/NO340408B1/no not_active IP Right Cessation
- 2011-09-06 JP JP2011193635A patent/JP2012019793A/ja not_active Withdrawn
2014
- 2014-09-29 NO NO20141168A patent/NO20141168L/no not_active Application Discontinuation
- 2014-10-15 JP JP2014210566A patent/JP2015044830A/ja active Pending

Also Published As

Publication number	Publication date
HU227189B1 (en)	2010-10-28
JP2009102321A (ja)	2009-05-14
NZ334721A (en)	2001-01-26
PL190041B1 (pl)	2005-10-31
NO328443B1 (no)	2010-02-22
JP2012019793A (ja)	2012-02-02
JP2009060918A (ja)	2009-03-26
EP2374876A2 (en)	2011-10-12
NO991225L (no)	1999-05-10
NO20141168L (no)	1999-05-10
HU230275B1 (hu)	2015-11-30
EP1538202A3 (en)	2007-05-30
ES2581828T3 (es)	2016-09-07
JP4313381B2 (ja)	2009-08-12
JP2015044830A (ja)	2015-03-12
JP5590788B2 (ja)	2014-09-17
IL184637A0 (en)	2009-09-22
DE69732129T2 (de)	2005-12-08
HUP9904666A3 (en)	2001-09-28
IL128960A0 (en)	2000-02-17
HK1022173A1 (zh)	2000-07-28
EP2374876A3 (en)	2012-10-24
AU4424497A (en)	1998-04-02
NO340408B1 (no)	2017-04-18
NO330687B1 (no)	2011-06-06
KR20050084473A (ko)	2005-08-26
JP4313405B2 (ja)	2009-08-12
CA2265464C (en)	2007-06-26
ATE286120T1 (de)	2005-01-15
HU1000445D0 (en)	2010-11-29
CA2265464A1 (en)	1998-03-19
EP2374876B1 (en)	2016-04-13
JP4001925B2 (ja)	2007-10-31
DK1538202T3 (en)	2014-03-24
JP2001504324A (ja)	2001-04-03
HK1074058A1 (en)	2005-10-28
EP2327775A2 (en)	2011-06-01
KR100547402B1 (ko)	2006-02-01
NO991225D0 (no)	1999-03-12
CN1230220A (zh)	1999-09-29
RU2179034C2 (ru)	2002-02-10
WO1998011206A3 (en)	1998-08-13
EP0935651B1 (en)	2004-12-29
PT1538202E (pt)	2014-04-22
DE69732129D1 (de)	2005-02-03
WO1998011206A2 (en)	1998-03-19
NO20110496L (no)	1999-05-10
JP2007289201A (ja)	2007-11-08
JP2007000145A (ja)	2007-01-11
HU9904666A (en)	2000-05-28
CN1268741C (zh)	2006-08-09
HK1162580A1 (en)	2012-08-31
PL332188A1 (en)	1999-08-30
DK2374876T3 (en)	2016-05-30
IL184637A (en)	2015-07-30
EP1538202B1 (en)	2014-01-22
ES2458292T3 (es)	2014-04-30
MX340738B (es)	2016-07-22
NZ506214A (en)	2002-11-26
KR20000036078A (ko)	2000-06-26
EP1538202A2 (en)	2005-06-08
IL128960A (en)	2007-10-31
EP0935651A2 (en)	1999-08-18
ES2234032T3 (es)	2005-06-16
EP2327775A3 (en)	2012-10-24
TW585919B (en)	2004-05-01

Publication	Publication Date	Title
NO20090583L (no)	1999-05-10	Terapi for alfa-galaktosidase A-mangel
ID30373A (id)	1997-01-23	PARAHERKUAMIDA ANTIPARASIT (Pecahan P-962086)
DE69738979D1 (de)	2008-10-23	Prozesssteuerungssystem
KR950700779A (ko)	1995-02-20	단백질의 정제방법(Protein purification)
DE59510718D1 (de)	2003-07-17	System zur kontaminationsfreien Bearbeitung von Reaktionsabläufen
IL122718A0 (en)	1998-08-16	Methods for treating diabetes
IT1285870B1 (it)	1998-06-24	Analizzatore ottico.
FI99108B (fi)	1997-06-30	Menetelmä hissin ohjaamiseksi
FI953370A0 (fi)	1995-07-07	Menetelmä NDIR-mittalaitteen lyhyen Fabry-Perot inMenetelmä NDIR-mittalaitteen lyhyen Fabry-Perot interferometrin ohjaamiseksi terferometrin ohjaamiseksi
FI941522L (fi)	1994-10-03	Menetelmä hemoglobiiniadditiotuotteiden määrittämiseksi
PT1027339E (pt)	2004-05-31	Metodo e reagentes para a n-alquilacao de ureidos
FI971264L (fi)	1997-03-26	Menetelmä 2,6-di-isopropyylifenolin puhdistamiseksi
DK0638068T3 (da)	1999-11-22	Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
NO982911D0 (no)	1998-06-22	FremgangsmÕte for behandling av depresjon
EP0609903A3 (en)	1997-05-02	Program language compiling system.
MA23936A1 (fr)	1997-04-01	Dimaleate de n,n-diethyl-8, 8-dipropyl-2-azaspiro (4,5) decane -2-propanamine
MD676F1 (ro)	1997-02-28	Metoda de tratament al rinosinuzitelor Method for treatment of the rhinosinusitis
ITTO950389A0 (it)	1995-05-16	Imbrago per deambulatore
IT236919Y1 (it)	2000-08-31	Centralina c.p.l. per ascensori
KR970048912U (ko)	1997-08-12	보행기의 지지프레임 가이드장치
IT1282168B1 (it)	1998-03-16	Apparecchiatura per timbrare pelli.
SE9502125D0 (sv)	1995-06-12	Behandlingsförfarande för trävirke
ITTO930166A0 (it)	1993-03-10	Procedimento per il trattamento di flussi reflui della produzione di n-fosfonometilglicina.
NL1002496A1 (nl)	1996-07-11	Loopwagen.
BR9504020A (pt)	1997-10-14	Gabarito reculavel p/ vãos

Legal Events

Date	Code	Title	Description
2017-10-09	MK1K	Patent expired